Display options
Cite
Amato CM, Hintzsche JD, Wells K, et al. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071943.
Amato, C. M., Hintzsche, J. D., Wells, K., Applegate, A., Gorden, N. T., Vorwald, V. M., Tobin, R. P., Nassar, K., Shellman, Y. G., Kim, J., Medina, T. M., Rioth, M., Lewis, K. D., McCarter, M. D., Gonzalez, R., Tan, A. C., & Robinson, W. A. (2020). Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers, 12(7), . https://doi.org/10.3390/cancers12071943
Amato, Carol M, et al. "Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071943
Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, Tan AC, Robinson WA. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers (Basel). 2020 Jul 17;12(7). doi: 10.3390/cancers12071943. PMID: 32708981; PMCID: PMC7409244.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jul 17;12(7). doi: 10.3390/cancers12071943.

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.

Cancers

Carol M Amato, Jennifer D Hintzsche, Keith Wells, Allison Applegate, Nicholas T Gorden, Victoria M Vorwald, Richard P Tobin, Kelsey Nassar, Yiqun G Shellman, Jihye Kim, Theresa M Medina, Matthew Rioth, Karl D Lewis, Martin D McCarter, Rene Gonzalez, Aik-Choon Tan, William A Robinson

Affiliations

  1. Department of Medicine, Division of Medical Oncology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA.
  2. Willamette Valley Cancer Institute and Research Center, Corvallis, OR 97330, USA.
  3. Saint Alphonsus Cancer Institute, Boise, ID 83706, USA.
  4. Department of Surgery, Division of Surgical Oncology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA.
  5. Department of Dermatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA.
  6. Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA.

PMID: 32708981 PMCID: PMC7409244 DOI: 10.3390/cancers12071943

Abstract

Immunotherapy, such as anti-PD1, has improved the survival of patients with metastatic melanoma. However, predicting which patients will respond to immunotherapy remains a significant knowledge gap. In this study we analyzed pre-immunotherapy treated tumors from 52 patients with metastatic melanoma and monitored their response based on RECIST 1.1 criteria. The responders group contained 21 patients that had a complete or partial response, while the 31 non-responders had stable or progressive disease. Whole exome sequencing (WES) was used to identify biomarkers of anti-PD1 response from somatic mutations between the two groups. Variants in codons G34 and G41 in

Keywords: CD83; NFKB; RNA sequencing; anti-PD1; biomarker; immunotherapy; melanoma; whole exome sequencing

References

  1. J Clin Invest. 2017 Aug 1;127(8):2930-2940 - PubMed
  2. Cancer Cell. 2019 Feb 11;35(2):238-255.e6 - PubMed
  3. Cell. 2016 Mar 24;165(1):35-44 - PubMed
  4. Immunobiology. 2002 Jul;205(3):231-46 - PubMed
  5. Nucleic Acids Res. 2012 Jul;40(Web Server issue):W452-7 - PubMed
  6. Am J Hum Genet. 2016 Nov 3;99(5):1190-1198 - PubMed
  7. Nat Methods. 2010 Apr;7(4):248-9 - PubMed
  8. J Exp Med. 2015 Jun 1;212(6):833-43 - PubMed
  9. Blood. 2006 Feb 15;107(4):1528-36 - PubMed
  10. Leuk Lymphoma. 2008 May;49(5):974-83 - PubMed
  11. J Clin Oncol. 2018 May 10;36(14):1428-1439 - PubMed
  12. Mol Immunol. 2008 Jul;45(12):3502-4 - PubMed
  13. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  14. Blood. 2016 Dec 8;128(23):2666-2670 - PubMed
  15. Front Immunol. 2019 Jun 07;10:1312 - PubMed
  16. Lancet Oncol. 2016 Dec;17(12):e542-e551 - PubMed
  17. JCI Insight. 2018 Jun 7;3(11): - PubMed
  18. Int J Cancer. 1989 Sep 15;44(3):554-9 - PubMed
  19. Nat Biotechnol. 2013 Jan;31(1):46-53 - PubMed
  20. EMBO J. 1997 Mar 17;16(6):1413-26 - PubMed
  21. Nucleic Acids Res. 2002 Jan 1;30(1):207-10 - PubMed
  22. Mol Immunol. 2019 Sep;113:16-21 - PubMed
  23. Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52 - PubMed
  24. J Hematol Oncol. 2017 Apr 24;10(1):88 - PubMed
  25. Trends Biochem Sci. 2004 Feb;29(2):72-9 - PubMed
  26. Cancer Immunol Immunother. 2008 Feb;57(2):265-70 - PubMed
  27. PLoS Genet. 2012 Sep;8(9):e1002949 - PubMed
  28. Nat Med. 2019 Dec;25(12):1916-1927 - PubMed
  29. Nat Protoc. 2012 Mar 01;7(3):562-78 - PubMed
  30. Haematologica. 2018 Apr;103(4):655-665 - PubMed
  31. Biochem Soc Trans. 2014 Feb;42(1):76-81 - PubMed
  32. Diagn Pathol. 2020 May 11;15(1):50 - PubMed
  33. N Engl J Med. 2017 Nov 9;377(19):1824-1835 - PubMed
  34. Br J Cancer. 2004 Jul 19;91(2):355-8 - PubMed
  35. Oncogene. 2008 Sep 18;27(42):5635-42 - PubMed
  36. N Engl J Med. 2018 May 10;378(19):1789-1801 - PubMed
  37. Cell Syst. 2015 Dec 23;1(6):417-425 - PubMed
  38. J Invest Dermatol. 2017 Sep;137(9):1984-1994 - PubMed
  39. Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):227-41 - PubMed
  40. Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14459-64 - PubMed
  41. J Clin Oncol. 2007 Apr 10;25(11):1341-9 - PubMed
  42. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1834-40 - PubMed
  43. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  44. J Invest Dermatol. 2014 Feb;134(2):452-460 - PubMed
  45. J Am Med Inform Assoc. 2016 Jul;23(4):721-30 - PubMed
  46. Nature. 2018 Jan 18;553(7688):347-350 - PubMed
  47. Melanoma Res. 2017 Jun;27(3):189-199 - PubMed
  48. Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034 - PubMed
  49. Mol Cancer Ther. 2017 Nov;16(11):2598-2608 - PubMed
  50. Signal Transduct Target Ther. 2017;2: - PubMed
  51. Nature. 2017 May 11;545(7653):175-180 - PubMed
  52. Ann Oncol. 2019 Apr 1;30(4):582-588 - PubMed
  53. Mol Cancer. 2013 Aug 02;12:86 - PubMed
  54. N Engl J Med. 2015 Jan 22;372(4):311-9 - PubMed
  55. Nat Genet. 2015 Oct;47(10):1194-9 - PubMed

Publication Types

Grant support